Unknown PHASE3 INTERVENTIONAL NCT00002771

Chemotherapy, Interferon, and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia

PROSPECTIVE CONTROLLED STUDY FOR THE OPTIMIZATION OF THERAPY IN CHRONIC MYELOID LEUKEMIA (CML): MULTICENTRIC STUDY FOR THE EVALUATION OF INTERFERON ALPHA VS ALLOGENIC BM TRANSPLANTATION WITH CHEMOTHERAPY IN CML

Sponsor: German CML Study Group

Conditions Leukemia

Interventions allogeneic bone marrow transplantation autologous bone marrow transplantation busulfan cytarabine hydroxyurea idarubicin peripheral blood stem cell transplantation radiation therapy recombinant interferon alfa

Updated 5 times since 2017 Last updated: Aug 1, 2013 Started: Jan 31, 1995

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00002771, this PHASE3 trial focuses on Leukemia and remains ongoing. Sponsored by German CML Study Group, it has been updated 5 times since 1995, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE3
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE3

First recorded

Jan 1995

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

German CML Study Group

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Mannheim, Germany